FibroGen (FGEN) Misses Q2 EPS by 20c

FibroGen (NASDAQ: FGEN) reported Q2 EPS of ($0.90), $0.20 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $44.32 million versus the consensus estimate of $34.73 million.

For earnings history and earnings-related data on FibroGen (FGEN) click here.

You May Also Be Interested In

• Ulta Beauty lifts guidance after Q3 results beat estimates
• Academy Sports and Outdoor (ASO) Misses Q3 EPS by 24c, Updates Guidance
• Morgan Stanley says PagerDuty stock is 'too cheap to ignore'; Shares gain after earnings